Universal Sequencing Technology Corporation Announces High-Throughput Solution For NGS Library Preparation
UST releases high-throughput solution enabling second-generation short-read sequencers to produce long-range results in greater capacity.
With this expanded indexing capability, our customers/TELL-
When used in combination with the UST's TELL-Seq High Throughput kit, researchers will be able to take advantage of the ultra-long linked-read results to provide unparalleled genomic information up to and exceeding 200Kb gDNA fragments with applications ranging from WGS, phasing, SV detection, metagenomics, and more for small, medium, and large genomes.
With TELL-Seq NGS technology, we've made library preparation easy. Our products effectively improve performance, time, and budget across a broad range of sample types with a proven track record.
Dr. Zhoutao (Tom) Chen, Chief Scientific Officer of UST, stated, "We are further streamlining the TELL-seq workflow by simplifying sample preparation and scaling up throughput in response to increased customer demands."
UST's TELL-Seq is a patent-pending transposase-
Dr. Aaron U. Levy, GM & Chief Commercial Officer of UST, stated, "TELL-Seq Linked-Long-
Universal Sequencing Technology Corporation (UST), a Boston and San Diego-based NGS biotechnology company, was established by a group of NGS veterans. UST is dedicated to developing the most advanced DNA sequencing technologies and has filed more than 20 provisional patent applications covering linked read NGS library preparation, single-cell sequencing, and groundbreaking 3rd-generation DNA sequencing technologies. UST is poised to lead the next wave of DNA sequencing innovations.
Dr. Aaron Levy, CCO & GM
Universal Sequencing Technology Corporation
Page Updated Last on: Oct 24, 2022